title: A global burden of gastric cancer: the major impact of China.
abstract: Gastric cancer (GC) is a highly aggressive cancer and a major cause of cancer-related deaths worldwide. Approximately half of the world's GC cases and deaths occur in china. GC presents challenges in early diagnosis and effective therapy due to a lack of understanding of the underlying molecular biology. The primary goals of this review are to outline current GC research in china and describe future trends in this field. Areas covered: This review mainly focuses on a series of GC-related advances China has achieved. Considerable progress has been made in understanding the role of H. pylori in GC by a series of population-based studies in well-established high-risk areas; A few germline and somatic alterations have been identified by 'omics' studies; Studies on the mechanisms of malignant phenotypes have helped us to form an in-depth understanding of GC and advance drug discovery. Moreover, identification of potential biomarkers and targeted therapies have facilitated the diagnosis and treatment of GC. However, many challenges remain. Expert commentary: To combat GC, sufficient funding is important. More attention should be paid on early diagnosis and the discovery of novel efficient biomarkers and the development of biomarker-based or targeted therapeutics in GC.
authors.affiliation: a State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases , Fourth Military Medical University , Xi'an , China.
authors.forename: Yongzhan
authors.initials: Y
authors.lastname: Nie
authors.affiliation: a State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases , Fourth Military Medical University , Xi'an , China.
authors.forename: Kaichun
authors.initials: K
authors.lastname: Wu
authors.affiliation: b Department of Medicine and Therapeutics and Institute of Digestive Disease , Chinese University of Hong Kong , Hong Kong , China.
authors.forename: Jun
authors.initials: J
authors.lastname: Yu
authors.affiliation: b Department of Medicine and Therapeutics and Institute of Digestive Disease , Chinese University of Hong Kong , Hong Kong , China.
authors.forename: Qiaoyi
authors.initials: Q
authors.lastname: Liang
authors.affiliation: a State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases , Fourth Military Medical University , Xi'an , China.
authors.forename: Xiqiang
authors.initials: X
authors.lastname: Cai
authors.affiliation: a State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases , Fourth Military Medical University , Xi'an , China.
authors.forename: Yulong
authors.initials: Y
authors.lastname: Shang
authors.affiliation: a State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases , Fourth Military Medical University , Xi'an , China.
authors.forename: Jinfeng
authors.initials: J
authors.lastname: Zhou
authors.affiliation: c Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Cancer Epidemiology, Peking University School of Oncology , Peking University Cancer Hospital & Institute , Beijing , China.
authors.forename: Kaifeng
authors.initials: K
authors.lastname: Pan
authors.affiliation: d Tumor Etiology and Screening, Department of Cancer Institute and General Surgery , The First Affiliated Hospital of China Medical University , Shenyang , China.
authors.forename: Liping
authors.initials: L
authors.lastname: Sun
authors.affiliation: e Renji Hospital , Shanghai Jiao-Tong University School of Medicine , Shanghai , China.
authors.forename: Jingyuan
authors.initials: J
authors.lastname: Fang
authors.affiliation: d Tumor Etiology and Screening, Department of Cancer Institute and General Surgery , The First Affiliated Hospital of China Medical University , Shenyang , China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Yuan
authors.affiliation: c Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Cancer Epidemiology, Peking University School of Oncology , Peking University Cancer Hospital & Institute , Beijing , China.
authors.forename: Weicheng
authors.initials: W
authors.lastname: You
authors.affiliation: a State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases , Fourth Military Medical University , Xi'an , China.
authors.forename: Daiming
authors.initials: D
authors.lastname: Fan
mesh_terms: D014408:Biomarkers, Tumor; D002681:China; D019175:DNA Methylation; D019008:Drug Resistance, Neoplasm; D020031:Epstein-Barr Virus Infections / Q000150:complications; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D014943:Global Health; D016481:Helicobacter Infections / Q000150:complications; D016480:Helicobacter pylori; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism; D058990:Molecular Targeted Therapy; D014411:Neoplastic Stem Cells; D011110:Polymorphism, Genetic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D013274:Stomach Neoplasms / Q000209:etiology* / Q000628:therapy*
chemical_list: D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D035683:MicroRNAs; D018719:Erb-b2 Receptor Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; C508053:ERBB2 protein, human
keywords: Gastric cancer; H. pylori; biomarker; early diagnosis; targeted therapy